These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 12507286)

  • 1. The immunohistochemical expression of metallothionein in inflammatory bowel disease. Correlation with HLA-DR antigen expression, lymphocyte subpopulations and proliferation-associated indices.
    Ioachim E; Michael M; Katsanos C; Demou A; Tsianos EV
    Histol Histopathol; 2003 Jan; 18(1):75-82. PubMed ID: 12507286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression of metallothionein in inflammatory bowel disease.
    Brüwer M; Schmid KW; Metz KA; Krieglstein CF; Senninger N; Schürmann G
    Inflamm Res; 2001 Jun; 50(6):289-93. PubMed ID: 11475329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease.
    Kruidenier L; Kuiper I; Van Duijn W; Mieremet-Ooms MA; van Hogezand RA; Lamers CB; Verspaget HW
    J Pathol; 2003 Sep; 201(1):17-27. PubMed ID: 12950013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases.
    Vuckovic S; Florin TH; Khalil D; Zhang MF; Patel K; Hamilton I; Hart DN
    Am J Gastroenterol; 2001 Oct; 96(10):2946-56. PubMed ID: 11693331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presence and possible significance of immunohistochemically demonstrable metallothionein expression in pterygium versus pinguecula and normal conjunctiva.
    Tsironi S; Ioachim E; Machera M; Aspiotis M; Agnanti N; Psilas K
    Eye (Lond); 2001 Feb; 15(Pt 1):89-96. PubMed ID: 11318304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localization of metallothionein in urothelial carcinoma of the human urinary bladder: an immunohistochemical study including correlation with HLA-DR antigen, p53, and proliferation indices.
    Ioachim EE; Charchanti AV; Stavropoulos NE; Athanassiou ED; Michael MC; Agnantis NJ
    Anticancer Res; 2001; 21(3B):1757-61. PubMed ID: 11497256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants.
    Kruidenier L; Kuiper I; Lamers CB; Verspaget HW
    J Pathol; 2003 Sep; 201(1):28-36. PubMed ID: 12950014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical Profile of Tumor Suppressor Proteins RASSF1A and LATS1/2 in Relation to p73 and YAP Expression, of Human Inflammatory Bowel Disease and Normal Intestine.
    Nterma P; Panopoulou E; Papadaki-Petrou E; Assimakopoulou M
    Pathol Oncol Res; 2020 Jan; 26(1):567-574. PubMed ID: 30604274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical HLA-DR antigen expression with lymphocyte subsets and proliferative activity in pterygium.
    Tsironi S; Ioachim E; Machera M; Aspiotis M; Agnantis N; Psillas K
    In Vivo; 2002; 16(5):299-306. PubMed ID: 12494867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of interleukin-12 and -17 in active inflammatory bowel disease.
    Nielsen OH; Kirman I; Rüdiger N; Hendel J; Vainer B
    Scand J Gastroenterol; 2003 Feb; 38(2):180-5. PubMed ID: 12678335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of HLA-DR antigens by colonic epithelium in inflammatory bowel disease.
    Selby WS; Janossy G; Mason DY; Jewell DP
    Clin Exp Immunol; 1983 Sep; 53(3):614-8. PubMed ID: 6577996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical expression of metallothionein in benign premalignant and malignant epithelium of the larynx: correlation with p53 and proliferative cell nuclear antigen.
    Ioachim E; Assimakopoulos D; Peschos D; Zissi A; Skevas A; Agnantis NJ
    Pathol Res Pract; 1999; 195(12):809-14. PubMed ID: 10631715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
    Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H
    Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Th17-inducing activity of CD14+ CD163 low myeloid cells in intestinal lamina propria of patients with Crohn's disease.
    Ogino T; Nishimura J; Barman S; Kayama H; Uematsu S; Okuzaki D; Osawa H; Haraguchi N; Uemura M; Hata T; Takemasa I; Mizushima T; Yamamoto H; Takeda K; Doki Y; Mori M
    Gastroenterology; 2013 Dec; 145(6):1380-91.e1. PubMed ID: 23993972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA-DR antigens on colonic epithelial cells in inflammatory bowel disease: I. Relation to the state of activation of lamina propria lymphocytes and to the epithelial expression of other surface markers.
    Fais S; Pallone F; Squarcia O; Biancone L; Ricci F; Paoluzi P; Boirivant M
    Clin Exp Immunol; 1987 Jun; 68(3):605-12. PubMed ID: 3308219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory bowel disease: susceptibility and disease heterogeneity revealed by human leukocyte antigen genotyping.
    Bouzid D; Kammoun A; Amouri A; Mahfoudh N; Haddouk S; Tahri N; Makni H; Masmoudi H
    Genet Test Mol Biomarkers; 2012 Jun; 16(6):482-7. PubMed ID: 22224635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical localization of macrophage CD68+, HLA-DR+, L1+ and CD44+ subsets in uterine endometrium during different phases of menstrual cycle.
    Kar M; Sengupta J; Kumar S; Bhargava VL; Ghosh D
    Indian J Physiol Pharmacol; 2004 Jul; 48(3):293-303. PubMed ID: 15648401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-DR antigen expression in pterygium epithelial cells and lymphocyte subpopulations: an immunohistochemistry study.
    Ioachim-Velogianni E; Tsironi E; Agnantis N; Datseris G; Psilas K
    Ger J Ophthalmol; 1995 Mar; 4(2):123-9. PubMed ID: 7795511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation.
    Olsen T; Rismo R; Cui G; Goll R; Christiansen I; Florholmen J
    Cytokine; 2011 Dec; 56(3):633-40. PubMed ID: 21945121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between serum interleukin-17 level and inflammatory bowel disease.
    Liu QL; Huang L; Zhao QJ; Li Q; He Z
    J Biol Regul Homeost Agents; 2016; 30(1):181-8. PubMed ID: 27049090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.